Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Internal Commitments and Discovery (NCE) Pipeline
BB106
Ketamine
Acute Pain Management
Mental Health Indications
BB206
Flumazenil
Benzodiazepine Addiction
BB605
Naloxone (Continuous Delivery)
Opioid Overdose
Bexson's science team is uniquely suited to develop New Chemical Entities targeting the NMDA receptor. We have established a new family of NMDA receptor antagonists with novel receptor binding profiles.
